BuzzFeed to cut 12% of its workforce

BuzzFeed to cut 12% of its workforce


The BuzzFeed website on a smartphone arranged in Hastings-on-Hudson, New York, on Monday, Dec. 6, 2021.

Tiffany Hagler-Geard | Bloomberg | Getty Images

BuzzFeed on Tuesday announced plans to cut its workforce by nearly 12%, or around 180 staffers.

The digital media company said the decision to lay off staff comes in response to challenging economic conditions, its acquisition of Complex Networks and an ongoing audience shift to short-form, vertical video.

The layoffs affect the sales, production, tech and content divisions for Complex and Buzzfeed, but not BuzzFeed News or HuffPost, according to the company.

Shares of BuzzFeed, which went public a year ago, hit a new low of $1.06 on Tuesday.

“In order for BuzzFeed to weather an economic downturn that I believe will extend well into 2023, we must adapt, invest in our strategy to serve our audience best, and readjust our cost structure,” CEO Jonah Peretti said in a memo to employees.

The company expects to cut most of the jobs by the end of the first quarter. As of March, the company had around 1,500 employees.

Last year, BuzzFeed went public via a special purpose acquisition vehicle, and shares fell nearly 40% in their first week of trading. In March, the company scaled back its news operation in an effort to make the division profitable. The restructuring saw the departure of several high-level editors.

Peretti said Tuesday that he wants the company to invest “in areas that will drive growth” and build “a more robust creator business.”



Source

Real estate could be the big winner in the private credit exodus
Business

Real estate could be the big winner in the private credit exodus

A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight to your inbox. Barely […]

Read More
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial
Business

Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial

Eli Lilly on Thursday said its next-generation obesity drug retatrutide cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.  The drug lowered hemoglobin A1c — a key measure of blood sugar levels — by an average of 1.7% to 2% across different doses at […]

Read More
FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More